Sigyn Therapeutics Appoints Dr. Christoph Zaba to Scientific Advisory Board to Advance Dialysis-Like Cardiovascular Therapy
Sigyn Therapeutics has appointed Dr. Christoph Zaba, an expert in extracorporeal therapies, to its Scientific Advisory Board to support the development of Sigyn Therapy™, a novel treatment designed to reduce cardiovascular disease risk factors using existing dialysis infrastructure.
Sigyn Therapeutics, Inc. has appointed Dr. Christoph Zaba to its Scientific Advisory Board, bringing extensive experience in medical technology and extracorporeal therapies to the company's development efforts. Dr. Zaba previously directed global product management in therapeutic apheresis at Fresenius Medical Care, advancing treatments across nephrology, dermatology, neurology, and cardiovascular medicine.
His expertise is particularly relevant to Sigyn Therapy™, a whole blood adsorption technology designed to reduce lipoprotein(a) and low-density lipoprotein cholesterol while simultaneously targeting inflammatory molecules that fuel cardiovascular disease progression. Cardiovascular disease remains the leading cause of global deaths, making this therapeutic approach particularly significant.
The appointment comes as Sigyn Therapeutics prepares to commence a multi-site clinical feasibility study of Sigyn Therapy™ in high-risk cardiovascular disease subjects with end-stage renal disease. Successful completion of this study could lead to a pivotal efficacy study necessary for potential market clearance. More information about the company's scientific advisory board can be found at https://www.sigyntherapeutics.com/about/scientific-advisory-board.
What makes Sigyn Therapy™ particularly noteworthy is its potential to address the significant access limitations of current lipoprotein apheresis treatments. While lipoprotein apheresis has demonstrated 55% to 98% reductions in major adverse cardiovascular events, treatment access is currently limited to fewer than 60 specialized apheresis centers in the United States. In contrast, Sigyn Therapy™ is designed for use on dialysis machines already located in approximately 7,500 U.S. dialysis clinics, potentially making this life-saving treatment accessible to a much broader patient population.
The technology represents a first-in-class approach to cardiovascular disease treatment, targeting both inflammatory drivers of disease progression and cholesterol-transporting lipoproteins that contribute to heart attacks, strokes, and other major adverse cardiovascular events. This dual-target mechanism could offer significant advantages over existing treatments by addressing multiple pathways of cardiovascular disease simultaneously.
Beyond cardiovascular applications, Sigyn Therapeutics is also developing dialysis-like cancer therapies, including ImmunePrep™ for immunotherapeutic antibody delivery optimization, ChemoPrep™ for enhanced chemotherapy targeting, and ChemoPure™ for chemotherapy toxicity reduction. The company plans to advance these cancer treatment candidates through joint venture development relationships, expanding its therapeutic pipeline beyond cardiovascular medicine.